Unlike the monolithic semiconductor industry, quantum computing encompasses varied approaches like superconducting, atomic, and photonic systems. Each has a distinct, partially overlapping supply chain, making a unified industrial policy incredibly difficult to formulate and execute.

While the race for quantum computing hardware is underway, a major blind spot is the software. Quantum software doesn't exist yet, and current software giants are not prepared. The U.S. needs a strategic public-private effort to build this ecosystem from scratch to capitalize on future hardware breakthroughs.

Major advancements in biotech instrumentation are not just software or AI achievements. They are the result of a deeply multidisciplinary effort over many years, requiring innovations and integration across optics, fluidics, chemistry, hardware, and biology to create powerful new tools.

Unlike AI, where software learnings diffuse rapidly, quantum progress is a 'hardware sport.' Tacit knowledge is deeply embedded in physical systems, making iteration times longer and knowledge transfer more difficult. This creates more defensible moats for companies and nations that achieve breakthroughs.

The quantum industry's structure, with its various modalities (like drug types) and long, high-risk development cycles, mirrors biotech. Policies should adopt similar models, like advanced market commitments and support for phase-based trials, to accelerate commercialization.

The narrative of China pursuing a single quantum pathway is outdated. Prominent Chinese academics are now founding private startups across multiple modalities, including neutral atoms and photonics, mirroring the diverse, competitive ecosystem of the West and signaling a more resilient national strategy.

To invest in high-risk, transformative fields like quantum computing, structure portfolios with three tiers: established leaders (e.g., IBM) forming the core, "enabler" companies providing key components (e.g., Honeywell), and a smaller allocation to purely speculative startups (e.g., IonQ) to capture upside while managing volatility.

Unlike semiconductors, where the U.S. has a substantial lead, quantum is a new field where the competitive moat is small. This creates a thin margin for error in industrial policy and R&D strategy, demanding a higher degree of precision from the outset.

The supply chain for today's quantum prototypes is globally distributed. The true geopolitical prize is to control the future, at-scale manufacturing ecosystem for fault-tolerant quantum computers—an arena where no nation currently has a decisive advantage.